secwatch.observer — SEC 8-K summary
======================================

Issuer:     Korro Bio, Inc. (KRRO)
CIK:        0001703647
Form:       8-K
Filed at:   2023-07-14T23:59:59+00:00
Accession:  0001193125-23-186853
Event type: m_and_a
Sentiment:  negative
Materiality: 1.00
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Frequency Therapeutics to merge with Korro Bio in all-stock deal; combined firm to focus on RNA editing, trade as KRRO
--------------------------------------------------------------------------------

- Pre-merger Frequency stockholders expected to own ~8% of combined company; Korro stockholders (incl. new investors) ~92%.
- Korro Bio secures $117M concurrent private financing co-led by Surveyor Capital and Cormorant; pro-forma cash ~$170M at close.
- Lead program: RNA editing therapy for AATD; preclinical data shows correction to 85% normal A1AT protein; IND planned H2 2024.
- Frequency discontinues its MS remyelination program; stockholders may receive CVR for future proceeds from that program.
- Merger expected to close Q4 2023, subject to Frequency stockholder approval; combined company led by Korro management.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703647/000119312523186853/0001193125-23-186853-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703647/000119312523186853/d529859d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-186853

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer